Goldline Pharmaceutical Summary
India's market for pharmaceutical marketing is predicted to experience steady growth in the coming years due to increasing awareness about health care, increasing cases of chronic diseases, and an increased rural distribution network in India. This trend will have a positive influence on Goldline Pharmaceuticals, as it is capable of utilising opportunities arising from increased consumer demand for branded generic medicines in cardiology, neurology, gastroenterology, paediatrics, and oncology wellness segments using an asset light marketing strategy.
Goldline Pharmaceutical Limited is a pharmaceutical marketing organisation based in Nagpur and operates using the company's own "Goldline" brand in five strategic sectors, including Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The company uses an asset-light strategy that enables the company to outsource production to 15 third-party WHO-GMP and ISO-certified companies and focus on marketing and distribution activities. It has over 146 varieties of drugs that cover several different medical specialities sold through 7 major distributors, mostly wholesalers in Maharashtra and Madhya Pradesh, accounting for over 76% of sales.
Looking into the financials of Goldline Pharmaceutical, one finds that the company has been consistently growing over the past few years. Based on restated figures, in FY25, the company has reported an operating income of ₹28.06 Cr and PAT of ₹2.83 Cr, with an EBITDA margin of 20.8% and a return on net worth of 27.38%. The EPS was ₹4.11, and net worth stood at ₹10.35 Cr as per FY25.
Goldline Pharmaceutical Limited has filed for a BSE SME IPO of 2,700,000 equity shares with a face value of ₹10 each, for a total issue size of ₹11.61 Cr with an offer price range of ₹41–₹43 per share, consisting of a fresh issue and market maker reservation, starting on May 12, 2026, and ending on May 14, 2026. Funds raised from the issue shall be utilised towards repayment of borrowings (₹8.90 Cr) and general corporate purposes. The issue is sponsored by Cumulative Capital Private Limited, book running lead manager, and Bigshare Services Private Limited, registrar to the issue.
Goldline Pharmaceutical Limited IPO Details:
Goldline Pharmaceutical Limited Issue Management:
Cumulative Capital Pvt.Ltd. acts as the book-running lead manager for Goldline Pharmaceutical BSE SME IPO, managing underwriting and compliance.
Goldline Pharmaceutical Limited IPO RTA (Registrar) Details:
Bigshare Services Pvt.Ltd. handles allotment, refunds, and demat credits - contact at +91-22-6263 8200 or ipo@bigshareonline.com.
Goldline Pharmaceutical Limited IPO Allotment Status:
To check your IPO allotment status:
Visit the Bigshare Services Pvt.Ltd. IPO Application Status page.
Select the company name from the dropdown menu.
Select and enter PAN, Application Number, DP/Client ID, or Account Number/IFSC.
Click Submit to view your allotment status.
Goldline Pharmaceutical Limited BSE SME IPO totals ₹11.61 crore, comprising a fresh issue of ₹11.61 crore reserved for the market-maker portion, with a net issue size after excluding the market-maker allocation is ₹11.02 Cr.
Goldline Pharmaceutical Limited IPO proceeds from the fresh issue of ₹11.02 crore will be deployed towards the following:
Goldline Pharmaceutical Limited BSE SME IPO offers shares with market maker reservation of ₹0.59 Cr excluded from the net public issue.
The anchor bidding for Goldline Pharmaceutical Limited's BSE SME IPO is scheduled for May 11, 2026, one day before the issue opens on May 12, 2026, and anchors will be allotted shares from the QIB pool. As per the IPO reservation, the QIB portion, including the anchor allocation, is not more than 50% of the net issue (1,281,000 shares), with the anchor sub-portion expected to be approximately 30% of the QIB allocation as per standard SEBI SME norms.
Lock-in: The anchor allotment follows standard SME IPO norms, where 50% of the anchor shares are locked in for 30 days and the remaining 50% for 90 days from the listing date. The issue is scheduled to list on May 19, 2026, on BSE SME.
The anchor allocation details will be disclosed in the anchor book before opening, and the registrar for the issue is Bigshare Services Pvt. Ltd.
As per the financials provided by the RHP, Goldline Pharmaceutical Limited has shown steady growth in recent years, thanks to its asset-light pharmaceutical marketing activities in Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar based on their unique "Goldline" brand, offering a range of 146 products in wellness specialities such as cardiology, neurology, gastroenterology, paediatrics, and oncology.
Total revenue in FY23, FY24, and FY25 was ₹19.85 crore, ₹23.57 crore, and ₹28.06 crore, respectively, with the company's PAT rising from ₹0.26 crore to ₹1.81 crore and ₹2.83 crore over the period – translating to an impressive 57% PAT growth between FY24 and FY25 with a PAT margin of 10.10% and EBITDA margin of 20.79% in FY25.
Among the major factors contributing to the growth, we have high demand for healthcare services in tier 2 and tier 3 cities, strategic partnerships with 15 WHO-GMP-certified pharmaceutical companies, and an extensive distribution network across 7 distributors, backed by the scalability of their asset-light business model, along with a robust ROE of 35.84%, ROCE of 38.46%, and post-issue P/E of 14.56x.
Action Links:
To apply for Goldline Pharmaceutical Limited IPO, open a demat account here
Goldline Pharmaceutical Limited IPO Subscription Status: Check live subscription here
Goldline Pharmaceutical Limited IPO GMP Update: Check latest grey market premium here
Goldline Pharmaceutical Key Highlights:
Goldline Pharmaceutical Limited is a Nagpur-based marketing company dealing in pharmaceuticals under its own branded range "Goldline", consisting of 5 business segments, i.e., Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness, having 146 products which cater to cardiology, neurology, gastroenterology, paediatrics, oncology wellness, and critical care segments.
The company adopts an asset-lite strategy and outsources their manufacturing from 15 GMP- and ISO-certified third parties and distributes the product through 7 major distributors from Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Revenue has increased from Rs.19.85 Cr in FY23 to Rs.23.57 Cr in FY24 and Rs.28.06 Cr in FY25, whereas the profit after tax has grown from Rs.0.26 Cr to Rs.1.81 Cr and Rs.2.83 Cr in FY25 from FY23, depicting 57% growth in PAT in FY24 and FY25. Over 76% revenue comes from Maharashtra and Madhya Pradesh, whereas the top 5 customers contribute to 78.36% revenue.
Goldline Pharmaceutical Risk Factors:
The risks of Goldline Pharmaceutical Limited's IPO are mentioned below:
Geographic concentration is quite significant as well because 76.42% of all sales are made in Maharashtra and Madhya Pradesh, meaning that the business is quite exposed to regional economic disturbances and potential changes in legislation within the state’s pharmaceutical industry.
The fact that five largest customers comprise 78.36% of the revenue shows the extent of risk that is connected with client concentration, where the loss of key customers can adversely affect revenue streams.
The heavy reliance on 15 different suppliers of third-party manufacturing of all products makes the company vulnerable to disruptions within the process of production.
Being a listed stock on BSE SME, liquidity should not be expected from the stock after the listing date, and trading volume is expected to be non-existent as well.
Competition with other large players in the market offering similar branded generics within all five of the company’s product segments may pose problems to the company.
Goldline Pharmaceutical Expert Analysis:
Goldline Pharmaceutical Limited's BSE SME book-built IPO has a total issue size of ₹11.61 Cr, comprising a fresh issue of ₹11.02 Cr and ₹0.59 Cr reserved for the market maker, at a price band of ₹41–₹43 per share (face value ₹10).
Basic details of the IPO:
Type of IPO: Book-built SME IPO (BSE SME)
Size of the issue: Minimum retail application 2 lots (6,000 shares, ₹258,000 at upper band). Lot size: 3,000 shares.
Uses of funds: Prepayment or repayment of outstanding borrowings (₹8.90 Cr) and general corporate purposes (₹2.12 Cr)
IPO opens: May 12, 2026 | IPO closes: May 14, 2026 | Listing: May 19, 2026 on BSE SME
Lead Manager: Cumulative Capital Pvt. Ltd. | Registrar: Bigshare Services Pvt. Ltd.
Expert View on the IPO:
Consistent profit margins have been seen in Goldline Pharmaceutical Company with robust growth in PAT by 57% in FY25, good ROE at 35.84%, good ROCE at 38.46%, and an appealing post-issue P/E at 14.56x when compared with its industry competitors such as Chandra Bhagat Pharma (P/E 37.73x) and Mono Pharmacare (P/E 12.57x). Nonetheless, the high level of debt of ₹11.03 Cr when the company has a low GMP of ₹0 shows lack of investor interest before the launch of the IPO.
Ideal for risk-prone investors looking for an investment in the Indian pharmaceuticals market that deals in the distribution of branded generic medicines using an asset-light approach.
Should you invest in Goldline Pharmaceutical?
Goldline Pharmaceutical Limited's IPO can be considered for growth-orientated investors seeking exposure to India's branded generic pharmaceutical marketing segment with improving margins and ROE, while accepting SME listing risks and client concentration concerns. Not recommended for conservative investors or those seeking immediate listing gains given the current GMP of ₹0.
Consider investing when:
Seeking exposure to an asset-light branded pharma marketing company with a scalable distribution model, improving PAT margins, and reasonable post-issue P/E of 14.56x.
Comfortable with BSE SME illiquidity and concentration risks in pharmaceutical distribution across a limited set of states and distributors.
Do not invest when:
Risk-averse about high client concentration (top 5 customers = 78.36% revenue) and geographic dependence on Maharashtra and Madhya Pradesh.
Seeking quick listing gains, the current GMP of ₹0 signals neutral to bearish market sentiment ahead of the May 12 opening.
Investors are advised to exercise discretion and refer to the full DRHP/RHP document before reaching any investment decision. This analysis is for informative purposes and not investment advice.
Action Links:
To apply for Goldline Pharmaceutical Limited's IPO, open a demat account here
Goldline Pharmaceutical Limited IPO Subscription Status: Check live subscription here
Goldline Pharmaceutical Limited IPO GMP Update: Check latest grey market premium here
1. What is the Goldline Pharmaceutical Limited IPO open and close date?
Goldline Pharmaceutical Limited's IPO opens on May 12, 2026, and closes on May 14, 2026. The anchor bidding precedes the opening day.
Track Goldline Pharmaceutical Limited IPO subscription status live here from Finnpick.
2. What is the Goldline Pharmaceutical Limited IPO price band and lot size?
The price band for the Goldline Pharmaceutical IPO is ₹41–₹43 per share with a face value of ₹10 per share. The lot size is 3,000 shares, making the minimum retail investment approximately ₹129,000–₹258,000 at the upper price band.
3. What is Goldline Pharmaceutical Limited's IPO total size?
The total issue size of Goldline Pharmaceutical Limited's IPO is ₹11.61 Cr, comprising 27 lakh fresh issue equity shares. There is no Offer for Sale (OFS) component – the entire issue is a fresh issue, meaning all proceeds go directly to the company.
4. How to apply for the Goldline Pharmaceutical Limited IPO?
Open a demat here (Zerodha/Upstox/AngelOne) or ASBA by May 14, 4 PM. Monitor Goldline Pharmaceutical Limited IPO subscription tracker here. Ensure your demat account is active and your UPI mandate is approved before the closing time.
5. How to check Goldline Pharmaceutical Limited IPO allotment status?
The allotment date is on May 15th and can be checked on Bigshare Services' RTA portal using PAN/DP ID.
6. What is Goldline Pharmaceutical Limited's IPO GMP today and subscription status?
The current Grey Market Premium (GMP) stands at ₹0 as of May 7th, indicating a listing at the price range of ₹43 – check daily updates of Goldline Pharmaceutical Limited IPO GMP trends here and live subscription status here from the May 12th opening only on Finnpick.
7. What does Goldline Pharmaceutical Limited specialise in?
Goldline Pharmaceutical Limited is a Nagpur-based pharmaceutical marketing and distribution company, offering third-party manufactured products like antibiotics (AZITHREE), supplements (AMCLUE), and others across Maharashtra and beyond. It reported FY25 revenue of ₹28.06 Cr and PAT of ₹2.83 Cr.
8. When is the Goldline Pharmaceutical Limited IPO listing date?
The Goldline Pharmaceutical Limited IPO is scheduled to list on BSE SME on May 19, 2026, which is T+3 after the basis of allotment on May 15, 2026.
9. What are the Goldline Pharmaceutical Limited IPO proceeds utilisation details?
The fresh IPO proceeds of ₹11.61 Cr will be utilised for repayment of borrowings (approx. ₹8.90 Cr) and general corporate purposes.
10. Who are the promoters of Goldline Pharmaceutical Limited?
The promoters of Goldline Pharmaceutical Limited are Mr. Amol Laxmikant Mujumdar (Chairman & Managing Director) and Mr. Swapan Premprakash Khandelwal, leading the company's pharma marketing expansion.
11. Should I apply for the Goldline Pharmaceutical IPO?
Goldline Pharmaceutical IPO is suited for investors seeking exposure to pharma marketing with strong PAT growth (ROE ~35%) and revenue uptick. However, note risks like third-party manufacturing reliance, regional focus, and SME listing liquidity before applying. This is not investment advice; refer to the full DRHP before making any investment decision.
